Pregnancy-Induced Changes

Uterine blood flow increases dramatically during pregnancy, rising from 50 to 100 mL/min before pregnancy to 700 to 900 mL/min at term, depending on the method of measurement ( Fig. 3.2 ). Studies in sheep have shown that increases in uterine blood flow can be divided into three phases. An initial phase, most likely controlled by the ovarian hormones estrogen and progesterone, occurs before and during implantation and early placentation. A second phase results from the growth and remodeling of the uteroplacental vasculature to support further placental development. The third phase results from progressive uterine artery vasodilation to meet the markedly increased nutrient requirements of the rapidly growing fetus. When expressed in terms of uterine weight, however, uterine flow per gram of tissue is particularly high in early gestation, and this ratio decreases as pregnancy progresses. In comparison, umbilical blood flow, expressed as a function of fetal weight, is relatively constant throughout most of pregnancy and is estimated to be 110 to 120 mL/min/kg. Uterine blood flow is increased in twin pregnancy, but the flow per unit of estimated fetal weight is similar to that in a singleton pregnancy. The progressive increase in uteroplacental blood flow during pregnancy is matched by a concurrent increase in blood flow on the fetal side (fetoplacental blood flow). However, despite suggestions of the possibility of intrinsic flow matching, it is believed that these circulations are independently regulated.

Changes in uterine artery blood flow with gestation.

(From Konje JC, Kaufmann P, Bell SC, Taylor DJ. A longitudinal study of quantitative uterine blood flow with the use of color power angiography in appropriate for gestational age pregnancies. Am J Obstet Gynecol. 2001;185:608–613.)

Distribution of Blood Flow

Uterine blood flow at term represents a greater proportion of cardiac output (approximately 12%) than in early pregnancy (approximately 3.5%). Regional distribution of blood flow within the pelvis also changes during gestation. Palmer et al. observed that increases in common iliac artery blood flow during pregnancy were associated with corresponding increases in uterine artery blood flow but also with decreases in external iliac artery blood flow. This pattern effectively constitutes a “steal” phenomenon, in which blood flow in the pelvis is preferentially redistributed toward the uterus ( Fig. 3.3 ).

Redistribution of blood flow in pelvic blood vessels during pregnancy determined unilaterally by Doppler ultrasonography.

Blood flow increased in the common iliac and uterine arteries but decreased in the external iliac artery, indicating that redistribution of flow favors uterine perfusion. Data are mean ± SEM.

(Modified from Palmer SK, Zamudio S, Coffin C, et al. Quantitative estimation of human uterine artery blood flow and pelvic blood flow redistribution in pregnancy. Obstet Gynecol. 1992;80:1000–1006.)

Primate studies have shown that 80% to 90% of total uterine blood flow perfuses the placenta at term, with the remainder supplying the myometrium and nonplacental endometrium. The placental and nonplacental vasculatures are anatomically and functionally distinct, and regulation of perfusion through these vascular beds differs. Therefore, it is important to differentiate studies that measure total uteroplacental blood flow versus placental blood flow.

Functional Classification

Placental vascular function varies among species. The human multivillous model is commonly believed to function as a “venous equilibrator,” in which oxygen tension in the umbilical vein approximates that in the uterine veins. In contrast, the placenta in some species (e.g., rodents) functions as a countercurrent exchanger. The more efficient function of the latter is reflected by the higher fetoplacental weight ratio in rodents (20 : 1) than in humans (6 : 1).

Autoregulation

Studies of pressure-flow relationships suggest that the nonpregnant uterine circulation exhibits autoregulation, alternately vasoconstricting or vasodilating in response to a number of different stimuli. In contrast, in pregnancy the placental and nonplacental circulations have differing properties. Animal studies have demonstrated that the uteroplacental circulation is a widely dilated, low-resistance system with perfusion that is largely pressure-dependent. However, a study in pregnant rabbits found that uteroplacental blood flow was relatively constant over a wide range of perfusion pressures. During hemorrhage in pregnant rats, uterine vascular resistance increased as systemic blood pressure and uterine blood flow decreased, thereby demonstrating an absence of autoregulation. Moreover, although the uteroplacental circulation is often considered to be maximally vasodilated with little or no ability for autoregulation, further vasodilation has been observed in response to systemically administered estrogen, prostacyclin, bradykinin, and acetylcholine. These discrepancies may be explained by changes in the nonplacental uterine vasculature, which accounts for a small fraction of total uteroplacental blood flow but appears to have similar autoregulatory responses during pregnant and nonpregnant states; this feature contrasts with the limited autoregulatory ability of the placental circulation. Laird et al. found that reducing arterial pressure by 22% with an inflatable aortic occluder in pregnant rabbits produced a reduction in total uteroplacental and placental blood flow but no significant change in myoendometrial blood flow. Clinically, limited autoregulation means that placental blood flow may diminish with reductions in maternal blood pressure (e.g., during hemorrhage or neuraxial anesthesia).

Margin of Safety

Studies in animals have demonstrated that, in normal physiologic conditions, uterine blood flow exceeds the minimum required to satisfy fetal oxygen demand. Although this feature confers a margin of safety that protects the fetus from fluctuations in uterine blood flow, decreases in fetal P o ₂ and progressive metabolic acidosis can occur with reductions in uteroplacental blood flow, depending on the magnitude and duration. However, the relationship between uterine blood flow and oxygen transfer appears nonlinear and suggests that uteroplacental blood flow can decrease by as much as 50% for limited periods before fetal oxygen uptake decreases and metabolic acidosis occurs.

Studies in sheep have shown that although uterine blood flow varies over a wide range, fetal oxygen uptake remains relatively constant, suggesting that the efficiency of oxygen extraction is greater when perfusion decreases. Using an inflatable balloon occluder around the terminal aorta to reduce uterine blood flow in sheep, Wilkening and Meschia found that at high levels of oxygen delivery, fetal oxygen uptake was not significantly affected by variations in uterine blood flow; moreover, fetal oxygen uptake became flow-dependent only when uterine oxygen delivery was reduced to less than half the baseline value. Boyle et al., investigating the effects of acute uterine arterial embolization with microspheres in sheep, found a linear decrease in fetal aortic oxygen tension as uterine blood flow decreased. However, uterine oxygen consumption did not decrease and fetal hydrogen ion concentration did not increase until uterine blood flow had decreased to approximately 50% of the baseline value. As uterine blood flow diminished, a reduction in uterine venous oxygen content and a greater arteriovenous oxygen content difference were observed, indicating an increase in oxygen extraction. Gu et al. reported comparable findings with the compression of the common uterine artery by an inflatable occluder in sheep.

Although the preceding experiments were conducted in sheep, the same principles may apply to humans. The human placenta, like the sheep placenta, is a relatively inefficient oxygen exchanger. Thus, in humans and sheep, the transfer rate of oxygen is affected less by decreases in placental perfusion than it is in animals with more efficient placentas, such as the rabbit and guinea pig. This difference may afford some protection in humans, because alterations in placental perfusion in animals with more efficient placentas frequently result in spontaneous abortion. Animal data would also suggest the presence of a significant physiologic buffer that protects the fetus during transient fluctuations in uteroplacental perfusion (e.g., changes in endogenous vasoconstrictor levels, uterine contractions, and parturition). This may partially explain why clinical studies have failed to demonstrate fetal acidosis when alpha-adrenergic agonists are used to maintain maternal blood pressure during neuraxial anesthesia, despite experimental data showing that these agents reduce uteroplacental perfusion in laboratory animals. These observations are based on an assumption of normal physiology; the presence of pathology likely diminishes any margin of safety.

Changes during Parturition

With the onset of the uterine contractions of labor, uteroplacental perfusion undergoes cyclical changes. During uterine contractions, a decrease in perfusion occurs that is inversely related to the strength of the contraction and the increase in intrauterine pressure. Conversely, during uterine relaxation, there is a period of hyperemia when perfusion is increased. Placental perfusion is believed to be more sensitive to these contraction-induced changes than myometrial or endometrial blood flow. Within the first few hours of parturition, uterine blood flow in sheep decreases on average by 50% or more, although there is notable interindividual variation.

Clinical Determinants of Uterine Blood Flow

In the acute setting, uterine blood flow is related to perfusion pressure (the difference between uterine arterial pressure and uterine venous pressure) and vascular resistance, as represented in the following equation:

There are several ways that uterine blood flow can decrease ( Box 3.1 ). First, uterine blood flow may decline with reductions in perfusion pressure because of decreased uterine arterial pressure (e.g., during systemic hypotension from hemorrhage, aortocaval compression, or sympathetic blockade during neuraxial anesthesia). Second, uterine blood flow may decline with reductions in perfusion pressure caused by increased uterine venous pressure (e.g., from vena caval compression, increased intrauterine pressure during uterine contractions, effects of drugs such as oxytocin and cocaine, and bearing down during the second stage of labor). Third, uterine blood flow may decline because of increased uterine vascular resistance (e.g., from endogenous vasoconstrictors released in response to stress, exogenous vasoconstrictors, and compression of endometrial spiral arterioles with uterine contractions).

Vascular Changes during Pregnancy

Because mean arterial pressure decreases slightly during pregnancy, the increase in uteroplacental blood flow is dependent on a substantial decrease in uterine vascular resistance ( Fig. 3.4 ), together with increased cardiac output and intravascular volume. The main factors contributing to the decrease in vascular resistance include vascular remodeling, changes in vascular reactivity, and the development of the widely dilated placental circulation.

Changes in uterine vascular resistance with gestation. Data are mean ± SE.

(Modified from Rosenfeld CR. Distribution of cardiac output in ovine pregnancy. Am J Physiol. 1977;232:H231–H235.)

Vascular remodeling of arteries in the uterus during pregnancy is believed to include increases in both vessel diameter and vessel length. In humans, both vessel lengthening and straightening of coiled vessels may occur ; the effects of changes in vessel diameter dominate, resulting in an overall decrease in resistance. Palmer et al., using serial Doppler studies during pregnancy, observed that uterine artery diameter is doubled by 21 weeks’ gestation, whereas there is no change in the diameter of the common iliac or external iliac arteries. These investigators also showed that uterine artery mean flow velocity increased progressively during pregnancy to values eight times greater than those of nonpregnancy. In parallel with arterial changes, there is also structural remodeling of uterine veins in pregnancy, including increases in diameter and distensibility and decreases in elastin content. Although blood viscosity decreases during pregnancy and also contributes to reduced uterine vascular resistance, this is considered a relatively minor effect compared with vascular changes.

Changes in vascular reactivity during pregnancy include a vasodilatory response that is meditated at endothelial and vascular smooth muscle levels. The growth of the placenta creates a low-resistance vascular pathway by eliminating the intramyometrial microcirculation and creating an intervillous space. This has functional characteristics of an arteriovenous shunt.

The mechanisms underlying the vascular changes during pregnancy are incompletely understood. Contributing factors include steroid hormones, decreased response to vasoconstrictors, endothelium-derived vasodilators, increased shear stress, and venoarterial exchange.

Steroid Hormones

Estrogen has a fundamental role in the short- and long-term uterine vascular changes during pregnancy. Plasma concentration of estrogen, initially derived from the ovaries and later predominantly from the placenta, rises concomitantly with the increase in uterine blood flow during pregnancy. Exogenously administered estrogen causes uterine vasodilation and a marked rise in uterine blood flow, independent of systemic effects. Angiogenic and vasodilatory effects of estrogen are meditated via estrogen receptors ER-α and ER-β, which are structurally and functionally distinct. Most of these receptors are located in the nucleus and mediate genomic effects by regulating transcription of genes that are particularly responsible for the longer-term uterine angiogenic responses. There are also membrane receptors that mediate nongenomic effects by up-regulating endothelial production of nitric oxide through the activation of endothelial nitric oxide synthase (eNOS) and the augmentation of eNOS protein expression.

Progesterone modulates the effect of estrogen on uterine blood flow. In a nonpregnant sheep model, exogenous progesterone administered alone had no uterine vasodilatory effect but had an inhibitory effect when combined with estrogen. Progesterone down-regulates expression of estrogen receptors. An increase in the estrogen-progesterone ratio parallels the increase in uterine blood flow in late pregnancy in many species.

Plasma cortisol levels approximately double during pregnancy. Cortisol has both systemic and local effects on uterine blood flow. Systemically, cortisol contributes to regulation of uterine blood flow by increasing plasma volume. Although cortisol is believed to decrease eNOS protein expression and decrease nitric oxide release, it potentiates the response to vasoconstrictor agents including angiotensin II, vasopressin, and norepinephrine. Attenuation of these effects occurs during pregnancy.

Decreased Response to Vasoconstrictors

In pregnancy, there is a generalized reduction in response to endogenous and exogenous vasoconstrictors, including angiotensin II, endothelin, thromboxane, epinephrine, norepinephrine, phenylephrine, serotonin, and arginine vasopressin. The relative refractoriness of the systemic and uterine circulations varies for different agents, which has important implications for the regulation and maintenance of uteroplacental blood flow.

During pregnancy, concentrations of angiotensin II in maternal blood are increased twofold to threefold ; however, the vasopressor response to angiotensin II is attenuated. This refractoriness is diminished in patients in whom preeclampsia develops. The uterine circulation is less responsive to angiotensin II than the systemic circulation. Thus, infusion of physiologic doses of angiotensin II has been shown to have minimal effect on uteroplacental blood flow while increasing systemic blood pressure. The difference in sensitivity of the uterine and systemic circulations to angiotensin II is considered an important physiologic adaptation during pregnancy that contributes to the redistribution of cardiac output, the increase in uterine blood flow, and possibly the maintenance of uterine blood flow during normal fluctuations in blood pressure.

Sensitivity to vasoconstrictors such as epinephrine , norepinephrine , and phenylephrine is attenuated during pregnancy. This may explain why relatively large doses of vasoconstrictors are often required to maintain blood pressure during spinal anesthesia for cesarean delivery. In contrast to the responses to angiotensin II, the uterine circulation is more responsive to these agents than the systemic circulation. Thus, during hemorrhage or other major stresses that result in large catecholamine release, it is unlikely that uteroplacental perfusion will be preferentially preserved above essential maternal perfusion.

The mechanism underlying the difference in vascular sensitivity between the uterine and systemic circulations is unclear, but distribution of receptor subtypes is believed to be important. For example, there are two distinct subtypes of angiotensin II receptors: AT ₁ R and AT ₂ R. In most tissues, including systemic vascular smooth muscle, AT ₁ R receptors are predominant and mediate vasoconstriction. However, AT ₂ R receptors, which do not mediate smooth muscle contraction, account for 75% to 90% of angiotensin II binding in uterine artery and myometrium.

Vasodilators

The greater synthesis and higher circulating concentrations of endothelial-derived vasodilators during pregnancy are believed to modulate systemic and uterine vascular responses to angiotensin II and other vasoconstrictors. Uterine vascular production of prostacyclin is greater than systemic vascular production, which probably contributes to maintaining uteroplacental blood flow in opposition to the effects of circulating vasoconstrictors. An enhanced response to angiotensin II during pregnancy has been demonstrated with the systemic and local infusion of indomethacin (which blocks prostacyclin production). However, inhibition of prostaglandin synthesis by an infusion of indomethacin induces only a transient decrease in uteroplacental blood flow, indicating that uteroplacental blood flow is not solely dependent on the continued production of prostacyclin.

Nitric oxide is synthesized from arginine in vascular endothelial cells and stimulates soluble guanylate cyclase in vascular smooth muscle, resulting in vascular relaxation through increases in cyclic guanosine monophosphate. Synthesis of nitric oxide is an important mechanism underlying changes in systemic and uterine vascular resistance, attenuated responses to vasoconstrictors, and vascular effects of estrogen during pregnancy. During pregnancy, uterine arteries have increased eNOS activity, higher levels of eNOS messenger ribonucleic acid and eNOS protein, and increased biosynthesis of nitric oxide and cyclic guanosine monophosphate. Removal of the vascular endothelium diminishes or eliminates the refractoriness of the uterine artery to vasoconstrictors, and inhibition of nitric oxide synthesis by N -nitro-L-arginine methyl ester (L-NAME) decreases uterine blood flow and also reverses refractoriness to vasoconstrictors. Long-term inhibition of nitric oxide synthase causes hypertension and fetal growth restriction in rats.

Other Vasoactive Substances

Atrial and brain natriuretic peptides attenuate the response to angiotensin II, and intravenous infusion of atrial natriuretic peptide reduces blood pressure while increasing uterine blood flow in preeclamptic women. Protein kinase C activity is decreased in uterine, but not systemic, arteries of pregnant sheep and may cause vasodilation and an increase in uterine blood flow; this may have a regulatory effect on local ovarian and placental estrogen production. Studies in rats have shown a decrease in endogenous endothelin-dependent vasoconstrictor tone in uteroplacental vessels, which may contribute to the increase in placental blood flow in late gestation. Uterine vascular resistance in early pregnancy may be increased by relaxin, which may have a role in modulating the effects of estrogen and progesterone. Placental protein 13 has been shown to be a potent vasodilator of both uterine and systemic blood vessels in vitro, and it has been suggested that this peptide might contribute to the vasodilation that occurs during human pregnancy. The use of vasopressin to prevent spinal anesthesia–induced hypotension has been reported in the care of patients with pulmonary hypertension, but its use as a vasoconstrictor in pregnancy has not been well studied.

Shear Stress

Shear stress, the frictional forces on the vessel wall from blood flow, is believed to be an important stimulus for uteroplacental vasodilation and remodeling. The reduction in downstream resistance resulting from the formation of the placenta would be expected to increase the upstream flow velocity and thus shear stress. Nitric oxide is considered an important mediator of this effect because increases in eNOS expression and nitric oxide production are witnessed with shear stress and because stripping the endothelium or pretreatment with L-NAME reduces or abolishes flow-induced vasodilation. Studies in vitro have shown that shear stress also increases endothelial production of prostacyclin.

Venoarterial Signaling

It has been postulated that growth factors or signal substances secreted by the placenta and/or myometrium could pass from uterine veins to adjacent uterine arteries; this may provide a system whereby the uterus and placenta regulate their own perfusion. Possible candidates for signal substances include vascular endothelial growth factor and placental growth factor. The importance of this mechanism in humans is uncertain.